Acuta Capital Partners, LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Acuta Capital Partners, LLC reported 33 stock positions worth $86.2 million. Its top holding was Ocular Therapeutix (OCUL) at 10.4% of the portfolio, followed by Insmed (INSM, 9.4%) and Tourmaline Bio (TRML, 7.5%). Compared with Q4 2024, it opened 7 new positions, sold out of 12, added to 19 and reduced 6. The biggest buy was a new position in Soleno Therapeutics (SLNO) and the biggest sale an exit from Crinetics Pharmaceuticals (CRNX).
- Most Recent 13F
- Q2 2026
- Location
- REDWOOD CITY, CA
- CIK
- 0001582844
- Portfolio Value
- $86.2M (Q1 2025)
- SEC Filing
- 0001104659-25-048878 ↗ filed May 15, 2025
Holdings Value
Holdings 33 stocks · $86.2M
| OCUL Ocular Therapeutix Inc. | 10.37% | 1,219,724 | $8.9M | Add +9.8% |
| INSM Insmed Inc. | 9.39% | 106,074 | $8.1M | Add +1.2% |
| TRML Tourmaline Bio Inc. | 7.53% | 426,882 | $6.5M | Add +21.3% |
| WHWK Whitehawk Therapeutics Inc. | 7.04% | 3,410,402 | $6.1M | Add +84.4% |
| ELVN Enliven Therapeutics Inc. | 6.06% | 265,269 | $5.2M | Reduce -0.8% |
| TRVI Trevi Therapeutics Inc. | 5.73% | 785,961 | $4.9M | Add +1.8% |
| SLNO Soleno Therapeutics Inc. | 5.56% | 67,136 | $4.8M | New |
| ARGX Argenx SE - ADR | 4.82% | 7,023 | $4.2M | Add +1.6% |
| ASND Ascendis Pharma A/S | 4.22% | 23,340 | $3.6M | Add +1.6% |
| PRAX Praxis Precision Medicines I | 3.83% | 87,141 | $3.3M | Add +29.1% |
| CDTX Cidara Therapeutics Inc. | 3.14% | 125,708 | $2.7M | Add +130.8% |
| OCS Oculis Holding AG | 2.76% | 125,000 | $2.4M | New |
| RVMD Revolution Medicines Inc. | 2.73% | 66,662 | $2.4M | Reduce -40.3% |
| LQDA Liquidia Corp. | 2.63% | 153,482 | $2.3M | Add +11.4% |
| DRUG Bright Minds Biosciences Inc. | 2.50% | 59,748 | $2.2M | Reduce -13.6% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 2.45% | 187,257 | $2.1M | Add +3.5% |
| MRK Merck & Co. Inc. | 2.39% | 22,994 | $2.1M | New |
| SRZN Surrozen Inc. | 2.30% | 170,000 | $2.0M | New |
| EWTX Edgewise Therapeutics Inc. | 2.18% | 85,454 | $1.9M | Reduce -2.5% |
| MREO Mereo Biopharma Group PL-ADR | 2.07% | 791,815 | $1.8M | Add +1.6% |
| UNICYCIVE THERAPEUTICS INC | 1.57% | 2,352,887 | $1.4M | Add +2.2% |
| JAZZ Jazz Pharmaceuticals PLC | 1.38% | 9,575 | $1.2M | New |
| VSTM Verastem Inc. | 1.23% | 176,000 | $1.1M | New |
| GILD Gilead Sciences Inc. | 1.21% | 9,298 | $1.0M | Add +1.6% |
| TERN Terns Pharmaceuticals Inc. | 1.04% | 325,550 | $899K | Reduce -27.3% |
| ZYME Zymeworks Inc. | 0.95% | 68,459 | $815K | Add +1.8% |
| RARE Ultragenyx Pharmaceutical Inc. | 0.89% | 21,290 | $771K | Add +1.4% |
| VERV Verve Therapeutics Inc. | 0.86% | 162,724 | $744K | Add +1.6% |
| RCKT Rocket Pharmaceuticals Inc. | 0.64% | 83,350 | $556K | Reduce -38.0% |
| RAPP Rapport Therapeutics Inc. | 0.19% | 16,400 | $164K | No change |
| FBRX Forte Biosciences Inc. | 0.17% | 18,469 | $143K | Add +1.8% |
| ARTV Artiva Biotherapeutics Inc. | 0.16% | 45,456 | $136K | Add +3.3% |
| ENLIVEN THERAPEUTICS INC | 0.00% | 115,805 | $0 | New |
Other holdings (1): bonds, preferreds, convertibles and warrants · $17K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | 90,832 | $17K | No change |
Total filed on the 13F, all lines: $86.2M.
Portfolio Sells Q4 2024 → Q1 2025
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −6.32 |
| PCVX Vaxcyte Inc. | Sold out | 0.00% | −3.71 |
| RVMD Revolution Medicines Inc. | Reduce -40.3% | 2.73% | −2.18 |
| MERSANA THERAPEUTICS INC | Sold out | 0.00% | −1.61 |
| TSHA Taysha Gene Therapies Inc. | Sold out | 0.00% | −1.54 |
| TECX Tectonic Therapeutic Inc. | Sold out | 0.00% | −1.53 |
| TERN Terns Pharmaceuticals Inc. | Reduce -27.3% | 1.04% | −1.45 |
| NAMS Newamsterdam Pharma Co. NV | Sold out | 0.00% | −1.29 |
| RCKT Rocket Pharmaceuticals Inc. | Reduce -38.0% | 0.64% | −1.06 |
| ELDN Eledon Pharmaceuticals Inc. | Sold out | 0.00% | −0.98 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −0.83 |
| SGMOQ Sangamo Therapeutics Inc. | Sold out | 0.00% | −0.76 |
| THRD Third Harmonic Bio Inc. | Sold out | 0.00% | −0.52 |
| CRVS Corvus Pharmaceuticals Inc. | Sold out | 0.00% | −0.40 |
| CELC Celcuity Inc. | Sold out | 0.00% | −0.33 |
| EWTX Edgewise Therapeutics Inc. | Reduce -2.5% | 2.18% | −0.17 |
| DRUG Bright Minds Biosciences Inc. | Reduce -13.6% | 2.50% | −0.01 |
| ELVN Enliven Therapeutics Inc. | Reduce -0.8% | 6.06% | +0.00 |
Portfolio Buys Q4 2024 → Q1 2025
| SLNO Soleno Therapeutics Inc. | New | 5.56% | +5.56 |
| OCS Oculis Holding AG | New | 2.76% | +2.76 |
| TRVI Trevi Therapeutics Inc. | Add +1.8% | 5.73% | +2.53 |
| MRK Merck & Co. Inc. | New | 2.39% | +2.39 |
| SRZN Surrozen Inc. | New | 2.30% | +2.30 |
| INSM Insmed Inc. | Add +1.2% | 9.39% | +2.11 |
| CDTX Cidara Therapeutics Inc. | Add +130.8% | 3.14% | +1.67 |
| JAZZ Jazz Pharmaceuticals PLC | New | 1.38% | +1.38 |
| VSTM Verastem Inc. | New | 1.23% | +1.23 |
| WHWK Whitehawk Therapeutics Inc. | Add +84.4% | 7.04% | +1.17 |
| ASND Ascendis Pharma A/S | Add +1.6% | 4.22% | +1.04 |
| LQDA Liquidia Corp. | Add +11.4% | 2.63% | +1.00 |
| OCUL Ocular Therapeutix Inc. | Add +9.8% | 10.37% | +0.82 |
| ARGX Argenx SE - ADR | Add +1.6% | 4.82% | +0.55 |
| BBOT Bridgebio Oncology Therapeut | Add +3.5% | 2.45% | +0.54 |
| GILD Gilead Sciences Inc. | Add +1.6% | 1.21% | +0.36 |
| TRML Tourmaline Bio Inc. | Add +21.3% | 7.53% | +0.35 |
| RARE Ultragenyx Pharmaceutical Inc. | Add +1.4% | 0.89% | +0.01 |
| ENLIVEN THERAPEUTICS INC | New | 0.00% | 0.00 |
| ZYME Zymeworks Inc. | Add +1.8% | 0.95% | −0.04 |
| VERV Verve Therapeutics Inc. | Add +1.6% | 0.86% | −0.05 |
| FBRX Forte Biosciences Inc. | Add +1.8% | 0.17% | −0.25 |
| UNICYCIVE THERAPEUTICS INC | Add +2.2% | 1.57% | −0.27 |
| ARTV Artiva Biotherapeutics Inc. | Add +3.3% | 0.16% | −0.29 |
| MREO Mereo Biopharma Group PL-ADR | Add +1.6% | 2.07% | −0.68 |
| PRAX Praxis Precision Medicines I | Add +29.1% | 3.83% | −1.40 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $143.5M | PRAX, WHWK, TNGX, STRO, AVBP |
| Q1 2026 | 26 | $140.6M | PRAX, TERN, WHWK, TNGX, DRUG |
| Q4 2025 | 29 | $147.3M | TERN, PRAX, CDTX, OCUL, WHWK |
| Q3 2025 | 27 | $96.8M | OCUL, CDTX, TRML, WHWK, INSM |
| Q2 2025 | 27 | $71.6M | OCUL, CDTX, WHWK, SLNO, TRML |
| Q1 2025 | 33 | $86.2M | OCUL, INSM, TRML, WHWK, ELVN |
| Q4 2024 | 38 | $99.4M | OCUL, INSM, TRML, CRNX, ELVN |
| Q3 2024 | 40 | $123.5M | PCVX, OCUL, TRML, INSM, ELVN |
| Q2 2024 | 31 | $118.6M | OCUL, ELVN, PCVX, DYN, PRAX |
| Q1 2024 | 32 | $153.9M | OCUL, PRAX, MERSANA THERAPEUTICS INC, TSHA, RCKT |